Does Rallies show Form 4 insider transactions for ACON?

Yes. Rallies tracks ACON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ACON research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACON. It does not provide personalized investment advice.

ACON (Aclarion, Inc. Common Stock) Stock Analysis - Insider Trades

Aclarion, Inc. Common Stock (ACON) is a publicly traded Healthcare sector company. As of May 21, 2026, ACON trades at $3.14 with a market cap of $7.88M and a P/E ratio of -0.36. ACON moved +2.19% today. Year to date, ACON is -38.42%; over the trailing twelve months it is -54.10%. Its 52-week range spans $2.34 to $3,499.51. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces ACON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ACON stock inside the company?

Recent ACON insider activity includes Breidbart Scott bought 5.66K, Neal David K bought 2.50K, Ness Brent bought 6.29K, Wesemann William bought 1.56K, and Ness Brent bought 10. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ACON Key Metrics

Key financial metrics for ACON
Metric	Value
Price	$3.14
Market Cap	$7.88M
P/E Ratio	-0.36
EPS	$-9.03
Dividend Yield	0.00%
52-Week High	$3,499.51
52-Week Low	$2.34
Volume	15
Avg Volume	0
Revenue (TTM)	$77.88K
Net Income	$-8.05M
Gross Margin	19.35%

Recent ACON Insider Trades

Breidbart Scott bought 5.66K (~$18.01K) on May 12, 2026.
Neal David K bought 2.50K (~$7.75K) on May 11, 2026.
Ness Brent bought 6.29K (~$20.00K) on May 11, 2026.
Wesemann William bought 1.56K (~$5.15K) on May 6, 2026.
Ness Brent bought 10 (~$62) on Nov 26, 2025.

Latest ACON News

Aclarion Logs 196% Scan Volume Surge, CEO Buys Shares and Unveils $2.5M Buyback — May 11, 2026
Aclarion Grants 17,000-Share Option at $3.20 to Commercial Director — May 6, 2026
Aclarion Secures Second Weill Cornell Agreement for Two-Year Nociscan and BMAC Trial — May 5, 2026
Aclarion Q1 Scan Volumes Jump 196% as $2.5M Buyback Boosts Cash Position — Apr 30, 2026
Aclarion Names Daniel Keefe Western U.S. Director After Triple-Digit Nociscan Growth — Apr 28, 2026

ACON Analyst Consensus

1 analysts cover ACON: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.

Common questions about ACON

Who is trading ACON stock inside the company?: Recent ACON insider activity includes Breidbart Scott bought 5.66K, Neal David K bought 2.50K, Ness Brent bought 6.29K, Wesemann William bought 1.56K, and Ness Brent bought 10. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ACON?: Yes. Rallies tracks ACON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ACON research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACON. It does not provide personalized investment advice.